Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.28)
# 396
Out of 5,237 analysts
524
Total ratings
48.95%
Success rate
17.89%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Reiterates: Buy | $1,245 | $331.81 | +275.21% | 32 | Apr 7, 2026 | |
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $48 → $41 | $41.02 | -0.05% | 29 | Apr 1, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $34 → $22 | $17.20 | +27.91% | 17 | Mar 31, 2026 | |
| NERV Minerva Neurosciences | Maintains: Neutral | $4 → $7 | $5.63 | +24.33% | 16 | Mar 12, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $53 → $74 | $55.78 | +32.66% | 6 | Mar 10, 2026 | |
| BHVN Biohaven | Maintains: Neutral | $11 → $10 | $9.08 | +10.13% | 18 | Mar 4, 2026 | |
| TBPH Theravance Biopharma | Maintains: Buy | $27 → $15 | $16.52 | -9.20% | 18 | Mar 4, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $33 → $34 | $28.96 | +17.40% | 24 | Mar 4, 2026 | |
| ARGX argenx SE | Maintains: Buy | $915 → $940 | $813.28 | +15.58% | 42 | Feb 27, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $34 | $21.24 | +60.08% | 5 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $0.5 | $0.25 | +101.86% | 20 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $29.06 | +20.44% | 24 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $13 | $6.32 | +105.70% | 30 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $117 | $103.50 | +13.04% | 36 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $22.74 | +67.11% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $5 | $3.17 | +57.73% | 19 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $40 | $38.43 | +4.09% | 3 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.52 | +376.19% | 18 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $3.82 | +318.85% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $35.47 | +29.69% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.05 | +129.51% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $69.23 | +70.45% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $36.55 | +121.61% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.95 | +258.97% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.87 | +862.57% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.88 | +40,716.33% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.97 | +408.91% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $118.96 | +52.99% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $5.00 | +275.00% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $36.32 | -50.44% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $35.84 | -77.68% | 7 | Jun 11, 2019 |
Praxis Precision Medicines
Apr 7, 2026
Reiterates: Buy
Price Target: $1,245
Current: $331.81
Upside: +275.21%
Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Neutral
Price Target: $48 → $41
Current: $41.02
Upside: -0.05%
Viridian Therapeutics
Mar 31, 2026
Maintains: Buy
Price Target: $34 → $22
Current: $17.20
Upside: +27.91%
Minerva Neurosciences
Mar 12, 2026
Maintains: Neutral
Price Target: $4 → $7
Current: $5.63
Upside: +24.33%
Xenon Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $53 → $74
Current: $55.78
Upside: +32.66%
Biohaven
Mar 4, 2026
Maintains: Neutral
Price Target: $11 → $10
Current: $9.08
Upside: +10.13%
Theravance Biopharma
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $15
Current: $16.52
Upside: -9.20%
Roivant Sciences
Mar 4, 2026
Maintains: Buy
Price Target: $33 → $34
Current: $28.96
Upside: +17.40%
argenx SE
Feb 27, 2026
Maintains: Buy
Price Target: $915 → $940
Current: $813.28
Upside: +15.58%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $34
Current: $21.24
Upside: +60.08%
Feb 18, 2026
Reiterates: Neutral
Price Target: $0.5
Current: $0.25
Upside: +101.86%
Feb 10, 2026
Reiterates: Buy
Price Target: $35
Current: $29.06
Upside: +20.44%
Feb 3, 2026
Maintains: Buy
Price Target: $20 → $13
Current: $6.32
Upside: +105.70%
Jan 30, 2026
Maintains: Buy
Price Target: $80 → $117
Current: $103.50
Upside: +13.04%
Jan 9, 2026
Reiterates: Buy
Price Target: $38
Current: $22.74
Upside: +67.11%
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $3.17
Upside: +57.73%
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $38.43
Upside: +4.09%
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $2.52
Upside: +376.19%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $3.82
Upside: +318.85%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $35.47
Upside: +29.69%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.05
Upside: +129.51%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $69.23
Upside: +70.45%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $36.55
Upside: +121.61%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.95
Upside: +258.97%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.87
Upside: +862.57%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.88
Upside: +40,716.33%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.97
Upside: +408.91%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $118.96
Upside: +52.99%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $5.00
Upside: +275.00%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $36.32
Upside: -50.44%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $35.84
Upside: -77.68%